Navigation Links
ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
Date:9/18/2009

MADISON, Conn., Sept 18 /PRNewswire/ -- Further results from the initial clinical trial of the ClariVein(TM) catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Friday, September 25, at the 23rd Annual Meeting of the Eastern Vascular Society in Philadelphia. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

Speaking is Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount Sinai Hospital, NY and the Director of The Centers for Vein Disease at Mount Sinai and Englewood Hospitals. Dr. Elias is the principle investigator of the trial, which was conducted at Englewood Hospital and Medical Center, NJ. Thirty patients were studied in this IRB-regulated trial.

"Initial results were very encouraging, and the success rates continue to be excellent as we follow patients over a longer period," Dr. Elias states. "The success rates are equal to the early results of radiofrequency or laser treatment of great saphenous vein disease. The main advantage is that the technique does not require tumescence anesthesia infusion, thus saving significant time and decreasing patient discomfort. In addition, no generator is required and capital and maintenance cost is reduced. This in-office procedure takes about 15 minutes to perform and patients resume normal activity that day. All patients would recommend the procedure to others."

The ClariVein(TM) catheter is a product of Vascular Insights LLC (http://vascularinsights.com) of Madison, CT. The company engages in the design, development, manufacture, and marketing of medical devices for the minimally invasive treatment of peripheral vascular disease. The company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ClariVein(TM) for infusion of physician-specified agents in the peripheral vasculature.

Dr. Elias is scheduled to speak at the 10:00 am scientific session at the Loews Philadelphia Hotel.

    Contact:

    Bill Kelly
    HarveyMalis Communications LLC
    bill@harveymalis.com
    203-375-2696


'/>"/>
SOURCE Vascular Insights LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to be Presented
2. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
3. 2,500 Cases Completed With the Magnetic Irrigated Catheter
4. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
5. New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation
6. Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
7. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
8. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
9. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
10. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
11. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):